Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 66
Filter
1.
J Med Chem ; 65(3): 2507-2521, 2022 02 10.
Article in English | MEDLINE | ID: mdl-35077161

ABSTRACT

Androgen receptor (AR) antagonists have been widely used for the treatment of prostate cancer (PCa). As a link between the AR and its transcriptional function, the activation function 2 (AF2) region has recently been revealed as a novel targeting site for developing AR antagonists. Here, we reported a series of N-(4-(benzyloxy)-phenyl)-sulfonamide derivatives as new-scaffold AR antagonists targeting the AR AF2. Therein, compound T1-12 showed excellent AR antagonistic activity (IC50 = 0.47 µM) and peptide displacement activity (IC50 = 18.05 µM). Furthermore, the in vivo LNCaP xenograft study confirmed that T1-12 offered effective inhibition on tumor growth when administered intratumorally. The study represents the first successful attempt to identify a small molecule targeting the AR AF2 with submicromolar AR antagonistic activity by structure-based virtual screening and provides important clues for the development of novel therapeutics for PCa treatment.


Subject(s)
Androgen Receptor Antagonists/therapeutic use , Antineoplastic Agents/therapeutic use , Prostatic Neoplasms/drug therapy , Receptors, Androgen/metabolism , Sulfonamides/therapeutic use , Androgen Receptor Antagonists/chemical synthesis , Androgen Receptor Antagonists/metabolism , Animals , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/metabolism , Binding Sites , Cell Proliferation/drug effects , Gene Expression/drug effects , Humans , Male , Mice, SCID , Molecular Docking Simulation , Molecular Structure , Protein Transport/drug effects , Receptors, Androgen/chemistry , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/metabolism , Xenograft Model Antitumor Assays
4.
J Antibiot (Tokyo) ; 74(10): 706-716, 2021 10.
Article in English | MEDLINE | ID: mdl-34282313

ABSTRACT

Prostate cancer (PC) is a leading cause of cancer-related death in men in Western countries. Androgen receptor (AR) signaling is a major driver of PC; therefore, androgen deprivation by medical and surgical castration is the standard treatment for patients with PC. However, over time, most patients will progress to metastatic castration-resistant PC. Enzalutamide is the only AR antagonist approved by the Food and Drug Administration for the treatment of metastatic castration-resistant PC. However, resistance to enzalutamide also develops in most patients with castration-resistant PC. Thus, there is an urgent need to develop new AR antagonists with new structures. For this purpose, we conducted both in silico and natural product screenings. From the in silico screening, we obtained T5853872 and more potent compound, STK765173. From the natural product screening, the novel compound arabilin was isolated from Streptomyces sp. MK756-CF1. Unlike STK765173, arabilin could overcome resistance to enzalutamide. Furthermore, we also extracted a novel compound, antarlide A, and its geometric isomers from Streptomyces sp. BB47. Antarlides A-F have novel 22-membered-ring macrocyclic structures, while antarlides G and H have 20-membered-ring structures. Both antarlides B and G showed potent AR antagonist activity in prostate cancer cells and could overcome resistance to enzalutamide.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Antineoplastic Agents/pharmacology , Benzamides/pharmacology , Drug Resistance, Neoplasm/drug effects , Nitriles/pharmacology , Phenylthiohydantoin/pharmacology , Prostatic Neoplasms/drug therapy , Streptomyces/drug effects , Androgen Receptor Antagonists/metabolism , Antineoplastic Agents/chemistry , Drug Evaluation, Preclinical , Humans , Male
5.
Chem Biol Drug Des ; 98(1): 60-72, 2021 07.
Article in English | MEDLINE | ID: mdl-33905591

ABSTRACT

Androgen receptor (AR) is an important target for the treatment of prostate cancer, and mutations in the AR have an important impact on the resistance of existing drugs. In this work, we performed molecular dynamics simulations of the existing marketed antiandrogens flutamide, nilutamide, bicalutamide, enzalutamide, apalutamide, darolutamide, and its main metabolite ORM15341 in complex with the wild-type and F876L mutant AR. We calculated the residue-specific binding free energy contribution of the wild-type and mutant ARs with the AS-IE method and analyzed the hotspot residues and the binding free energy contributions of specific residues before and after the mutation. In addition, we analyzed the total binding obtained by adding residue binding energy contributions and compared the results with experimental values. The obtained residue-specific binding information should be very helpful in understanding the mechanism of drug resistance with respect to specific mutations and in the design of new generation drugs against possible new mutations.


Subject(s)
Androgen Antagonists/metabolism , Androgen Receptor Antagonists/chemistry , Biomarkers, Tumor/metabolism , Receptors, Androgen/metabolism , Androgen Receptor Antagonists/metabolism , Flutamide/chemistry , Humans , Imidazolidines/chemistry , Male , Molecular Docking Simulation , Molecular Dynamics Simulation , Mutation , Phenylthiohydantoin/chemistry , Protein Binding , Protein Conformation , Structure-Activity Relationship , Thermodynamics , Thiohydantoins/chemistry
6.
Chem Biol Drug Des ; 97(5): 1059-1078, 2021 05.
Article in English | MEDLINE | ID: mdl-33470049

ABSTRACT

Sustained androgen receptor (AR) signaling and apoptosis evasion are among the main hurdles of castration-resistant prostate cancer (CRPC) treatment. We designed and synthesized isothiocyanate (ITC)-containing hybrid AR antagonist (ITC-ARi) and rationally combined ITC-ARi with GSH synthesis inhibitor buthionine sulfoximine (BSO) to efficiently downregulate AR/AR splice variant and induce ferroptosis in CRPC cells. The representative ITC-ARi 13 is an AR ligand that contains an N-acetyl cysteine-masked ITC moiety and gradually releases parental unconjugated ITC 12b in aqueous solution. The in vitro anti-PCa activities of 13, such as growth inhibition and AR downregulation, are significantly enhanced when combined with BSO. The drug combination caused notable lipid peroxidation and the cell viability was effectively rescued by iron chelator, antioxidants or the inhibitor of heme oxygenase-1, supporting the induction of ferroptosis. 13 and BSO cooperatively downregulate AR and induce ferroptosis likely through increasing the accessibility of 13/12b to cellular targets, escalating free intracellular ferrous iron and attenuating GSH-centered cellular defense and adaptation. Further studies on the combination of ITC-ARi and GSH synthesis inhibitor could result in a new modality against CRPC.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Down-Regulation/drug effects , Drug Design , Ferroptosis/drug effects , Isothiocyanates/chemistry , Androgen Receptor Antagonists/chemical synthesis , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/therapeutic use , Binding Sites , Buthionine Sulfoximine/pharmacology , Cell Line, Tumor , Cell Proliferation/drug effects , Cell Survival/drug effects , Glutathione/metabolism , Humans , Male , Molecular Docking Simulation , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/pathology , Protein Isoforms/chemistry , Protein Isoforms/genetics , Protein Isoforms/metabolism , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Transcriptional Activation/drug effects
7.
Chem Biol Drug Des ; 97(4): 821-835, 2021 04.
Article in English | MEDLINE | ID: mdl-33277796

ABSTRACT

Dimethylcurcumin (ASC-J9) is a curcumin analogue capable of inhibiting prostate cancer cell proliferation. The mechanism is associated with the unique role of ASC-J9 in enhancing androgen receptor (AR) degradation. So far, ASC-J9 has been investigated in typical AR-associated diseases such as prostate cancer, benign prostatic hypertrophy, bladder cancer, renal diseases, liver diseases, cardiovascular diseases, cutaneous wound, spinal and bulbar muscular atrophy, ovarian cancer and melanoma, exhibiting great potentials in disease control. In this review, the effects and molecular mechanisms of ASC-J9 on various AR-associated diseases are summarized. Importantly, the effects of ASC-J9 and AR antagonists enzalutamide/bicalutamide on prostate cancer are compared in detail and crucial differences are highlighted. At last, the pharmacological effects of ASC-J9 are summarized and the future applications of ASC-J9 in AR-associated disease control are discussed.


Subject(s)
Androgen Receptor Antagonists/therapeutic use , Curcumin/therapeutic use , Prostatic Neoplasms/drug therapy , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/pharmacology , Curcumin/analogs & derivatives , Curcumin/metabolism , Curcumin/pharmacology , Humans , Kidney Neoplasms/drug therapy , Kidney Neoplasms/pathology , Kidney Neoplasms/radiotherapy , Male , Prostatic Neoplasms/pathology , Prostatic Neoplasms/radiotherapy , Radiation Tolerance , Receptors, Androgen/chemistry , Receptors, Androgen/metabolism , Signal Transduction/drug effects , Urinary Bladder Neoplasms/drug therapy , Urinary Bladder Neoplasms/pathology , Urinary Bladder Neoplasms/radiotherapy
8.
Biol Pharm Bull ; 43(12): 1931-1939, 2020.
Article in English | MEDLINE | ID: mdl-33268711

ABSTRACT

Androgen receptor (AR) has a key role in the development and progression of prostate cancer, and AR antagonists are used for its remedy. Recently, carborane derivatives, which are carbon-containing boron clusters have attracted attention as new AR ligands. Here we determined the force field parameters of 10-vertex and 12-vertex p-carborane to facilitate in silico drug design of boron clusters. Then, molecular dynamics (MD) simulations of complexes of AR-carborane derivatives were performed to evaluate the parameters and investigate the influences of carborane derivatives on the three-dimensional structure of AR. Energy profiles were obtained using quantum chemical calculations, and the force-field parameters were determined by curve fitting of the energy profiles. The results of MD simulations indicated that binding of the antagonist-BA341 changed some hydrogen-bond formations involved in the structure and location of helix 12. Those results were consistent with previously reported data. The determined parameters are also useful for refining the structure of the carborane-receptor complex obtained by docking simulations and development of new ligands with carborane cages not only for AR but also for various receptors.


Subject(s)
Androgen Receptor Antagonists/chemistry , Boron Compounds/chemistry , Drug Delivery Systems/methods , Molecular Dynamics Simulation , Receptors, Androgen/chemistry , Androgen Receptor Antagonists/administration & dosage , Androgen Receptor Antagonists/metabolism , Boron Compounds/administration & dosage , Boron Compounds/metabolism , Protein Structure, Secondary , Receptors, Androgen/metabolism , Structure-Activity Relationship
9.
J Med Chem ; 63(21): 12642-12665, 2020 11 12.
Article in English | MEDLINE | ID: mdl-33095584

ABSTRACT

We report herein the design, synthesis, and pharmacological characterization of a library of novel aryl pyrazol-1-yl-propanamides as selective androgen receptor degraders (SARDs) and pan-antagonists that exert broad-scope AR antagonism. Pharmacological evaluation demonstrated that introducing a pyrazole moiety as the B-ring structural element in the common A-ring-linkage-B-ring nonsteroidal antiandrogens' general pharmacophore allowed the development of a new scaffold of small molecules with unique SARD and pan-antagonist activities even compared to our recently published AF-1 binding SARDs such as UT-155 (9) and UT-34 (10). Novel B-ring pyrazoles exhibited potent AR antagonist activities, including promising distribution, metabolism, and pharmacokinetic properties, and broad-spectrum AR antagonist properties, including potent in vivo antitumor activity. 26a was able to induce an 80% tumor growth inhibition of xenografts derived from the enzalutamide-resistant (Enz-R) VCaP cell line. These results represent an advancement toward the development of novel AR antagonists for the treatment of Enz-R prostate cancer.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Drug Resistance, Neoplasm/drug effects , Pyrazoles/chemistry , Receptors, Androgen/metabolism , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/therapeutic use , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Benzamides , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Design , Half-Life , Humans , Male , Mice , Microsomes, Liver/metabolism , Nitriles , Phenylthiohydantoin/analogs & derivatives , Phenylthiohydantoin/pharmacology , Phenylthiohydantoin/therapeutic use , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Pyrazoles/pharmacology , Pyrazoles/therapeutic use , Rats , Rats, Sprague-Dawley , Receptors, Androgen/chemistry , Structure-Activity Relationship , Xenograft Model Antitumor Assays
10.
Regul Toxicol Pharmacol ; 117: 104764, 2020 Nov.
Article in English | MEDLINE | ID: mdl-32798611

ABSTRACT

Screening certain environmental chemicals for their ability to interact with endocrine targets, including the androgen receptor (AR), is an important global concern. We previously developed a model using a battery of eleven in vitro AR assays to predict in vivo AR activity. Here we describe a revised mathematical modeling approach that also incorporates data from newly available assays and demonstrate that subsets of assays can provide close to the same level of predictivity. These subset models are evaluated against the full model using 1820 chemicals, as well as in vitro and in vivo reference chemicals from the literature. Agonist batteries of as few as six assays and antagonist batteries of as few as five assays can yield balanced accuracies of 95% or better relative to the full model. Balanced accuracy for predicting reference chemicals is 100%. An approach is outlined for researchers to develop their own subset batteries to accurately detect AR activity using assays that map to the pathway of key molecular and cellular events involved in chemical-mediated AR activation and transcriptional activity. This work indicates in vitro bioactivity and in silico predictions that map to the AR pathway could be used in an integrated approach to testing and assessment for identifying chemicals that interact directly with the mammalian AR.


Subject(s)
Androgen Receptor Antagonists/toxicity , Androgens/toxicity , Hazardous Substances/toxicity , Models, Theoretical , Receptors, Androgen , Androgen Receptor Antagonists/metabolism , Androgens/metabolism , Animals , Environmental Exposure/prevention & control , Environmental Exposure/statistics & numerical data , Hazardous Substances/metabolism , High-Throughput Screening Assays/methods , Humans , Receptors, Androgen/metabolism
11.
Cells ; 9(6)2020 06 16.
Article in English | MEDLINE | ID: mdl-32560058

ABSTRACT

Prostate cancer is the most commonly diagnosed malignancy in men. Its growth mainly relies on the activity of the androgen receptor (AR), justifying the use of androgen deprivation therapy as a gold standard treatment for the metastatic disease. Inhibition of the androgen axis using second generation antagonists has improved patients' survival, but is systematically confronted to resistance mechanisms, leading to a median survival that does not exceed 5 years. Counteracting this resistance has been the object of a large number of investigations, with a particular emphasis towards the identification of new AR inhibitors, whether they antagonize the receptor by a competitive or a non-competitive binding. To this end, many high content screens have been performed, to identify new non-steroidal AR antagonists, using a variety of approaches, but reported somewhat controversial results, depending on the approach and on the cell model that was used for screening. In our study, we used the U2OS osteosarcoma cells stably transfected with AR or ARv7 and a luciferase reporter as a previously validated model to screen the Prestwick Phytochemical library. The results of our screen identified ellipticine, harmol, and harmine hydrochloride as confirmed hits. Surprisingly, we could demonstrate that harmol hydrochloride, previously identified as a non-competitive inhibitor of AR or a weak inhibitor of androgen signaling, was actually a competitive antagonist of AR, which inhibits the growth of VCaP prostate cancer line, at concentrations for which it did not affect the growth of the AR negative DU145 and PC3 cells. Interestingly, we also report for the first time that harmol hydrochloride was selective for AR, as it could not alter the activity of other nuclear receptors, such as the glucocorticoid receptor (GR), the progesterone receptor (PR), or the mineralocorticoid receptor (MR). Additionally, we demonstrate that, conversely to enzalutamide, harmol hydrochloride did not show any agonistic activity towards the pregnane X receptor (PXR), a master regulator of drug metabolism. Together, our results shed light on the importance of the cellular context for the screening of new AR antagonists. They further indicate that some of the potential hits that were previously identified may have been overlooked.


Subject(s)
Androgen Antagonists/pharmacology , Drug Resistance, Neoplasm/drug effects , Prostatic Neoplasms/drug therapy , Receptors, Androgen/metabolism , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/pharmacology , Cell Proliferation/drug effects , Harmine , Humans , Male , Prostatic Neoplasms/pathology
12.
Biochem Biophys Res Commun ; 526(3): 756-763, 2020 06 04.
Article in English | MEDLINE | ID: mdl-32265027

ABSTRACT

Secretion of PDI from platelets and endothelial cells is an important step of all thrombotic events. In the absence of extracellular PDI thrombus formation and fibrin generation may be impaired. Thrombin-mediated PDI secretion is regulated by the stimulation of P2Y12 receptors. This paper provides evidences that P2Y12 antagonists or AR agonists may modulate release of PDI molecules from platelets and with less efficiency from endothelial cells. Moreover P2Y12 antagonization or AR agonization modulates platelet-endothelial interaction. We prove that combinations of P2Y12 antagonists and AR agonists inhibit platelet-dependent adhesion of cancer cells to endothelium and attenuate cancer cell invasiveness, but longer exposition to AR agonists may stimulate migration of invasive breast cancer cells through endothelium thus leading to increased metastasis.


Subject(s)
Androgen Receptor Antagonists/metabolism , Blood Platelets/metabolism , Endothelial Cells/metabolism , Protein Disulfide-Isomerases/metabolism , Purinergic P2Y Receptor Antagonists/metabolism , Receptors, Androgen/metabolism , Receptors, Purinergic P2Y12/metabolism , Blood Specimen Collection , Bodily Secretions , Breast Neoplasms/metabolism , Cell Line, Tumor , Cell Movement , Endothelium/metabolism , Female , Fibrin/metabolism , Humans , Neoplasm Metastasis , Platelet Adhesiveness , Signal Transduction , Sulfhydryl Compounds/chemistry , Thrombin/metabolism , Thrombosis/metabolism
13.
Clin Pharmacokinet ; 59(2): 229-244, 2020 02.
Article in English | MEDLINE | ID: mdl-31432469

ABSTRACT

BACKGROUND: Apalutamide is a next-generation androgen receptor inhibitor approved for treatment of subjects with high-risk, non-metastatic, castration-resistant prostate cancer (NM-CRPC). OBJECTIVE: The objective of this study was to characterize the population pharmacokinetics of apalutamide and its metabolite N-desmethyl-apalutamide in healthy male and castration-resistant prostate cancer subjects. METHODS: Plasma concentration data for apalutamide and N-desmethyl-apalutamide from 1092 subjects (seven clinical studies) receiving oral apalutamide (30-480 mg) once daily were pooled for a population pharmacokinetic analysis using a non-linear mixed-effect modelling approach. The impact of clinically relevant covariates was also assessed. RESULTS: Apalutamide absorption was rapid, and the apparent steady-state volume of distribution was large (276 L), reflecting a wide body distribution. Apalutamide was eliminated slowly, with its apparent clearance increasing from 1.31 L/h after the first dose to 2.04 L/h at steady state. No evidence of time-dependent disposition was observed for N-desmethyl-apalutamide, which was also widely distributed and slowly cleared (1.5 L/h). After 4 weeks of treatment, more than 95% of steady-state exposure of apalutamide and N-desmethyl-apalutamide was reached. At a dose of apalutamide 240 mg/day, apalutamide and N-desmethyl-apalutamide exposure exhibited 5.3- and 85.2-fold accumulation in plasma, respectively. Inter-individual variability in apalutamide apparent clearance is low (< 20%). Among the covariates evaluated, apalutamide and N-desmethyl-apalutamide exposure were statistically associated only with health status, body weight, and albumin concentration, and the effect was low (< 25%). CONCLUSIONS: A population pharmacokinetic modelling approach was successfully applied to describe the pharmacokinetics of apalutamide and N-desmethyl-apalutamide. No clinically relevant covariates were identified as predictors of apalutamide and N-desmethyl-apalutamide pharmacokinetics.


Subject(s)
Albumins/analysis , Androgen Receptor Antagonists/pharmacokinetics , Prostatic Neoplasms, Castration-Resistant/drug therapy , Thiohydantoins/pharmacokinetics , Adult , Aged , Aged, 80 and over , Androgen Receptor Antagonists/administration & dosage , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/therapeutic use , Biological Variation, Population/drug effects , Body Weight , Case-Control Studies , Health Status , Healthy Volunteers , Humans , Male , Middle Aged , Models, Theoretical , Predictive Value of Tests , Prostatic Neoplasms, Castration-Resistant/ethnology , Prostatic Neoplasms, Castration-Resistant/metabolism , Thiohydantoins/administration & dosage , Thiohydantoins/metabolism , Thiohydantoins/therapeutic use
14.
Life Sci Alliance ; 2(4)2019 08.
Article in English | MEDLINE | ID: mdl-31431473

ABSTRACT

Aberrant androgen signaling drives prostate cancer and is targeted by drugs that diminish androgen production or impede androgen-androgen receptor (AR) interaction. Clinical resistance arises from AR overexpression or ligand-independent constitutive activation, suggesting that complete AR elimination could be a novel therapeutic strategy in prostate cancers. IRC117539 is a new molecule that targets AR for proteasomal degradation. Exposure to IRC117539 promotes AR sumoylation and ubiquitination, reminiscent of therapy-induced PML/RARA degradation in acute promyelocytic leukemia. Critically, ex vivo, IRC117539-mediated AR degradation induces prostate cancer cell viability loss by inhibiting AR signaling, even in androgen-insensitive cells. This approach may be beneficial for castration-resistant prostate cancer, which remains a clinical issue. In xenograft models, IRC117539 is as potent as enzalutamide in impeding growth, albeit less efficient than expected from ex vivo studies. Unexpectedly, IRC117539 also behaves as a weak proteasome inhibitor, likely explaining its suboptimal efficacy in vivo. Our studies highlight the feasibility of AR targeting for degradation and off-target effects' importance in modulating drug activity in vivo.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Prostatic Neoplasms/metabolism , Receptors, Androgen/metabolism , Androgen Antagonists/metabolism , Androgen Receptor Antagonists/metabolism , Androgens/metabolism , Animals , Cell Line, Tumor , Cell Proliferation/drug effects , Drug Resistance, Neoplasm/drug effects , Humans , Male , Mice , Mice, Inbred BALB C , Mice, Nude , Prostate/metabolism , Prostatic Neoplasms/drug therapy , Signal Transduction/drug effects , Xenograft Model Antitumor Assays
15.
Nucleic Acids Res ; 47(8): 3828-3835, 2019 05 07.
Article in English | MEDLINE | ID: mdl-30838415

ABSTRACT

The crucial role of androgen receptor (AR) in prostate cancer development is well documented, and its inhibition is a mainstay of prostate cancer treatment. Here, we analyze the perturbations to the AR cistrome caused by a minor groove binding molecule that is designed to target a sequence found in a subset of androgen response elements (ARE). We find treatment with this pyrrole-imidazole (Py-Im) polyamide exhibits sequence selectivity in its repression of AR binding in vivo. Differentially changed loci are enriched for sequences resembling ARE half-sites that match the Py-Im polyamide binding preferences determined in vitro. Comparatively, permutations of the ARE half-site bearing single or double mismatches to the Py-Im polyamide binding sequence are not enriched. This study confirms that the in vivo perturbation pattern caused by a sequence specific polyamide correlates with its in vitro binding preference genome-wide in an unbiased manner.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Antineoplastic Agents/pharmacology , Imidazoles/pharmacology , Nylons/pharmacology , Prostatic Neoplasms/drug therapy , Pyrroles/pharmacology , Receptors, Androgen/genetics , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/metabolism , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/metabolism , Base Sequence , Binding Sites , Cell Line, Tumor , Dihydrotestosterone/pharmacology , Gene Expression , Humans , Imidazoles/chemistry , Imidazoles/metabolism , Male , Mice , Mice, SCID , Nylons/chemistry , Nylons/metabolism , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Pyrroles/chemistry , Pyrroles/metabolism , Receptors, Androgen/metabolism , Response Elements , Tumor Burden/drug effects , Xenograft Model Antitumor Assays
16.
Eur J Med Chem ; 166: 232-242, 2019 Mar 15.
Article in English | MEDLINE | ID: mdl-30711833

ABSTRACT

Prostate cancer (PCa) is the most frequently diagnosed male malignant tumor and remains the second leading cause of male cancer mortality in the western countries. The second-generation antiandrogen enzalutamide (ENZa) can prolong survival time for patients with mCRPC. However, the overexpression of glucocorticoids receptor (GR) in mCRPC cells causes the resistance of antiandrogen and leads to the failure of androgen receptor (AR) targeting therapy. Herein, based on the chemical structures of antiandrogen and crystal structure of GR, we set up to develop GR/AR (GR and AR) dual antagonist by virtual screening and biological evaluation. We identified Z19 as a dual AR/GR antagonist. Z19 inhibited the transcription activity of both AR and GR, reducing both protein and mRNA level of the downstream proteins of GR and AR signaling, and provided a potential lead compound for the development of novel treatment agents of prostate cancer. Our work demonstrates that rational drug design is an efficient strategy in development of the GR/AR dual antagonist for the treatment of prostate cancer.


Subject(s)
Androgen Receptor Antagonists/pharmacology , Drug Design , Receptors, Androgen/metabolism , Receptors, Glucocorticoid/antagonists & inhibitors , Androgen Receptor Antagonists/metabolism , Cell Proliferation/drug effects , Humans , Male , Molecular Docking Simulation , Prostatic Neoplasms/drug therapy , Prostatic Neoplasms, Castration-Resistant/drug therapy , Prostatic Neoplasms, Castration-Resistant/pathology , Protein Conformation , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Receptors, Glucocorticoid/chemistry , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Transcription, Genetic/drug effects , User-Computer Interface
17.
Article in English | MEDLINE | ID: mdl-29530944

ABSTRACT

Prostatic adenocarcinoma (PCa) remains a significant health concern. Although localized PCa can be effectively treated, disseminated disease remains uniformly fatal. PCa is reliant on androgen receptor (AR); as such, first-line therapy for metastatic PCa entails suppression of AR signaling. Although initially effective, recurrent tumors reactivate AR function, leading to a lethal stage of disease termed castration-resistant PCa (CRPC). Recent findings implicate AR signaling in control of DNA repair and show that alterations in DNA damage repair pathways are strongly associated with disease progression and poor outcome. This review will address the DNA repair alterations observed in the clinical setting, explore the anticipated molecular and cellular consequence of DNA repair dysfunction, and consider clinical strategies for targeting tumors with altered DNA repair.


Subject(s)
Adenocarcinoma/metabolism , Adenocarcinoma/pathology , Cell Transformation, Neoplastic/metabolism , DNA Damage , DNA Repair , Prostatic Neoplasms/metabolism , Prostatic Neoplasms/pathology , Adenocarcinoma/drug therapy , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/therapeutic use , Cell Transformation, Neoplastic/genetics , Disease Progression , Gene Expression Regulation, Neoplastic , Humans , Male , Prostatic Neoplasms/drug therapy , Targeted Gene Repair/methods
18.
Elife ; 72018 12 06.
Article in English | MEDLINE | ID: mdl-30520733

ABSTRACT

Pathways modulating glucose homeostasis independently of insulin would open new avenues to combat insulin resistance and diabetes. Here, we report the establishment, characterization, and use of a vertebrate 'insulin-free' model to identify insulin-independent modulators of glucose metabolism. insulin knockout zebrafish recapitulate core characteristics of diabetes and survive only up to larval stages. Utilizing a highly efficient endoderm transplant technique, we generated viable chimeric adults that provide the large numbers of insulin mutant larvae required for our screening platform. Using glucose as a disease-relevant readout, we screened 2233 molecules and identified three that consistently reduced glucose levels in insulin mutants. Most significantly, we uncovered an insulin-independent beneficial role for androgen receptor antagonism in hyperglycemia, mostly by reducing fasting glucose levels. Our study proposes therapeutic roles for androgen signaling in diabetes and, more broadly, offers a novel in vivo model for rapid screening and decoupling of insulin-dependent and -independent mechanisms.


Subject(s)
Glucose/metabolism , Hyperglycemia/genetics , Insulin/genetics , Receptors, Androgen/genetics , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/metabolism , Animals , Disease Models, Animal , Gene Knockout Techniques , Homeostasis , Hyperglycemia/metabolism , Hyperglycemia/pathology , Insulin Resistance/genetics , Receptors, Androgen/chemistry , Signal Transduction/genetics , Zebrafish/genetics
19.
Bioorg Med Chem ; 26(13): 3805-3811, 2018 07 30.
Article in English | MEDLINE | ID: mdl-29903411

ABSTRACT

Based on the co-crystal structure of bicalutamide with a T877A-mutated androgen receptor (AR), glycerol and aminoglycerol derivatives were designed and synthesized as a novel type of carborane-containing AR modulators. The (R)-isomer of 6c, whose chirality is derived from the glycerol group, showed 20 times more potent cell inhibitory activity against LNCaP cell lines expressing T877A-mutated AR than the corresponding (S)-isomer. Docking studies of both isomers with AR suggested that (R)-6c is in closer spatial proximity to helix-12 of the AR than (S)-6c, which is the most important common motif in the secondary structure of AR for the expression of antagonistic activity.


Subject(s)
Androgen Receptor Antagonists/chemical synthesis , Boranes/chemistry , Drug Design , Glycerol/chemistry , Receptors, Androgen/metabolism , Androgen Receptor Antagonists/metabolism , Androgen Receptor Antagonists/pharmacology , Binding Sites , Catalytic Domain , Cell Line, Tumor , Cell Proliferation/drug effects , Glycerol/metabolism , Glycerol/pharmacology , Humans , Molecular Docking Simulation , Mutagenesis, Site-Directed , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Stereoisomerism
20.
Toxicol Lett ; 294: 95-104, 2018 Sep 15.
Article in English | MEDLINE | ID: mdl-29777833

ABSTRACT

A critical literature review reveals that knowledge of side effects of pharmaceuticals diclofenac and paracetamol is extremely important because of their widespread use and occurrence in the environment. In order to delineate whether these compounds have endocrine activity and influence on the immune system, we assessed the potential endocrine disrupting and immunomodulatory activities of: diclofenac (DIC), its metabolite 4-hydroxydiclofenac (4-HD) and paracetamol (PAR). Herein, we report on their impact on estrogen receptor (ER), androgen receptor (AR), glucocorticoid receptor (GR) and thyroid hormone receptor (TR). The endocrine disrupting effects were assessed in vitro in MDA-kb2 and GH3.TRE-Luc cell lines and by the XenoScreen YES/YAS assay. Moreover, binding affinity to nuclear receptors (GR and AR) was also measured. Immunomodulatory properties of the compounds were evaluated in lymphoblastoid cell lines. All the tested compounds showed endocrine disrupting and immunomodulatory activities. The results revealed that both DIC and its metabolite 4-HD exhibited significant estrogenic, anti-androgenic (in YAS assay), (anti)-androgenic, (anti)-glucocorticoid and anti-thyroid hormonal activities (in luciferase reporter gene assays). DIC showed direct binding to the GR, while its metabolite 4-HD to the GR and AR. Only metabolite 4-HD showed estrogenic, androgenic (in YAS assay) and thyroid-hormonal activities. PAR had anti-androgenic activity and anti-thyroid hormonal activity. PAR displayed GR agonist activity with competition to its receptor and agonistic activity to AR. All of the compounds significantly modulated pro-inflammatory and immunoregulatory cytokine production in lymphoblastoid cell lines and were thus proven immunomodulatory. The study is useful in determining toxicological effects and contributes to the knowledge of possible side effects of diclofenac, its metabolite and paracetamol.


Subject(s)
Acetaminophen/adverse effects , Analgesics, Non-Narcotic/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Diclofenac/adverse effects , Endocrine Disruptors/adverse effects , Immunologic Factors/adverse effects , Lymphocytes/drug effects , Acetaminophen/chemistry , Acetaminophen/metabolism , Analgesics, Non-Narcotic/chemistry , Analgesics, Non-Narcotic/metabolism , Androgen Receptor Antagonists/adverse effects , Androgen Receptor Antagonists/chemistry , Androgen Receptor Antagonists/metabolism , Androgens/adverse effects , Androgens/chemistry , Androgens/metabolism , Anti-Inflammatory Agents, Non-Steroidal/chemistry , Anti-Inflammatory Agents, Non-Steroidal/metabolism , Binding, Competitive , Cell Line , Cell Survival/drug effects , Cells, Cultured , Cytokines/agonists , Cytokines/metabolism , Diclofenac/analogs & derivatives , Diclofenac/chemistry , Diclofenac/metabolism , Endocrine Disruptors/chemistry , Endocrine Disruptors/metabolism , Estrogens/adverse effects , Estrogens/chemistry , Estrogens/metabolism , Genes, Reporter/drug effects , Humans , Immunologic Factors/chemistry , Immunologic Factors/metabolism , Lymphocytes/cytology , Lymphocytes/immunology , Lymphocytes/metabolism , Receptors, Androgen/chemistry , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Receptors, Estrogen/chemistry , Receptors, Estrogen/genetics , Receptors, Estrogen/metabolism , Receptors, Glucocorticoid/agonists , Receptors, Glucocorticoid/antagonists & inhibitors , Receptors, Glucocorticoid/genetics , Receptors, Glucocorticoid/metabolism , Receptors, Thyroid Hormone/agonists , Receptors, Thyroid Hormone/antagonists & inhibitors , Receptors, Thyroid Hormone/genetics , Receptors, Thyroid Hormone/metabolism , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/metabolism , Structure-Activity Relationship
SELECTION OF CITATIONS
SEARCH DETAIL
...